Heterologous prime-boost with mRNA-1273 stimulates persistent neutralising antibodies in BBIBP-CorV-vaccinated individuals.
- Resource Type
- Academic Journal
- Authors
- Sharif H; PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei Darussalam. Electronic address: hanisah.sharif@ubd.edu.bn.; Ghani H; PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei Darussalam.; Ahmad L; PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei Darussalam.; Bagol S; Disease Control Division, Ministry of Health, Commonwealth Drive, Bandar Seri Begawan, Brunei Darussalam.; Wong J; Disease Control Division, Ministry of Health, Commonwealth Drive, Bandar Seri Begawan, Brunei Darussalam.; Tan CW; Programme in Emerging Infectious Diseases, Duke-NUS (National University of Singapore) Medical School, Singapore.; Zhu F; Programme in Emerging Infectious Diseases, Duke-NUS (National University of Singapore) Medical School, Singapore.; Wang LF; Programme in Emerging Infectious Diseases, Duke-NUS (National University of Singapore) Medical School, Singapore.; Naing L; PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei Darussalam.; Cunningham AC; PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei Darussalam.
- Source
- Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
- Subject
- Language
- English
BBIBP-CorV inactivated vaccine is one of the most prevalent vaccines globally, but immune responses are far less studied than novel COVID-19 vaccine platforms. Longitudinal studies on BBIBP-CorV with homologous and heterologous booster doses are limited. This study follows a subset of participants from a national study comparing the immunogenicity of COVID-19 vaccines and levels of SARS-CoV-2 neutralising antibody (NAb). Homologous and heterologous booster dose significantly increased NAb levels in BBIBP-CorV-vaccinated individuals. Similar NAb levels were observed 1 month following BNT162b2 or mRNA-1273 booster. Interestingly, NAb persisted following mRNA-1273 booster (n = 95), but waned significantly at 6 and 9 months following BNT162b2 booster (n = 50; P > 0.001). The persistence of NAb was also observed following breakthrough infection. This study provides evidence that not all mRNA vaccines are equal in the longer term and should provide valuable information for policy makers planning booster programmes for BBIBP-CorV vaccinated populations.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Chee Wah Tan and Linfa Wang are co-inventors of a patent on the surrogate virus neutralisation test.
(Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)